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Cardiomyocytes undergo growth and remodeling in re-
sponse to specific pathological or physiological conditions.
In the former, myocardial growth is a risk factor for cardiac
failure and faster protein synthesis is a major factor driving
cardiomyocyte growth. Our goal was to quantify the rapid
effects of different pro-hypertrophic stimuli on the synthe-
sis of specific proteins in ARVC and to determine whether
such effects are caused by alterations onmRNA abundance
or the translation of specific mRNAs. Cardiomyocytes have
very low rates of protein synthesis, posing a challenging
problem in terms of studying changes in the synthesis of
specific proteins, which also applies to other nondividing
primary cells. To study the rates of accumulation of specific
proteins in these cells, we developed an optimized version
of the Quantitative Noncanonical Amino acid Tagging
LC/MS proteomic method to label and selectively enrich
newly synthesized proteins in these primary cells while
eliminating the suppressive effects of pre-existing and
highly abundant nonisotope-tagged polypeptides. Our data
revealed that a classical pathologic (phenylephrine; PE) and
the recently identified insulin stimulus that also contributes
to the development of pathological cardiac hypertrophy
(insulin), both increased the synthesis of proteins involved
in, e.g. glycolysis, the Krebs cycle and beta-oxidation, and
sarcomeric components. However, insulin increased syn-
thesis of many metabolic enzymes to a greater extent than
PE. Using a novel validation method, we confirmed that
synthesis of selected candidates is indeed up-regulated by
PE and insulin. Synthesis of all proteins studied was up-
regulated by signaling through mammalian target of rapa-
mycin complex 1 without changes in their mRNA levels,
showing the key importance of translational control in the
rapid effects of hypertrophic stimuli. Expression of PKM2
was up-regulated in rat hearts following TAC. This isoform
possesses specific regulatory properties, so this finding
indicates it may be involved in metabolic remodeling and
also serve as a novel candidate biomarker. Levels of trans-
lation factor eEF1 also increased during TAC, likely contrib-
uting to faster cell mass accumulation. Interestingly those
two candidates were not up-regulated in pregnancy or
exercise induced CH, indicating PKM2 and eEF1 were
pathological CH specific markers. We anticipate that the
methodologies described here will be valuable for other
researchers studying protein synthesis in primary
cells. Molecular & Cellular Proteomics 15: 10.1074/
mcp.M115.054312, 3170–3189, 2016.
Cardiac hypertrophy (CH)1 describes the enlargement of
the myocardium and can be classified as either the ‘physio-
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logical’ or ‘pathological’ types. The latter is usually caused by
conditions such as chronic hypertension, and is initially an
adaptive response to help the heart to maintain normal func-
tion. However, sustained pressure overload leads to chronic
hypertrophy and myocardial dysfunction. Indeed, pathologi-
cal cardiac hypertrophy usually progresses into heart failure
and is a major cause of death in young adults in developed
countries. In contrast, physiological hypertrophy, as caused
by pregnancy or exercise, is beneficial (1–4).
The differences between pathological and physiological hy-
pertrophy are profound; for example, fetal genes such as
natriuretic peptides A and B are up-regulated in pathological,
but not physiological, hypertrophy (5). In pathological hyper-
trophy, cardiac function usually becomes impaired, whereas
in physiological hypertrophy, it is usually preserved or even
enhanced. Metabolic remodeling is another significant
change during cardiac hypertrophy. In pathological hypertro-
phy, fatty acid -oxidation decreases whereas glucose utili-
zation increases. In contrast, both fatty acid oxidation and
glucose oxidation are up-regulated in physiological hypertro-
phy. Pathological hypertrophy is also associated with mito-
chondrial dysfunction, fibrosis and cell apoptosis; in physio-
logical hypertrophy mitochondrial biogenesis is up-regulated,
and neither fibrosis nor apoptosis are observed. Furthermore,
distinct signaling pathways are activated in different types of
hypertrophy: in physiological hypertrophy, insulin-like growth
factor (IGF) 1 activates signaling via phosphoinositide 3-ki-
nase signaling while well-established inducers of pathological
hypertrophy, such as the 1-adrenergic agonist phenyleph-
rine (PE), which stimulates signaling through Gq and the
classical mitogen-activated protein kinase kinase/extracellu-
lar signal-regulated kinase (ERK) pathway (6). In both cases,
mTORC1 (mammalian target of rapamycin complex 1) signal-
ing is activated. Insulin activates the IGF-1 signaling pathway
at the supraphysiological concentration of 100 nmol/L, so was
believed to promote the physiological hypertrophic growth of
cardiomyocytes at this concentration similarly to IGF-1 (7).
However, a recent study showed that insulin signaling actually
contributes to the development of pathological cardiac hyper-
trophy (8). The relationship between pathological CH induced
by 1-adrenergic stimulation or by insulin has not previously
been explored, and doing this is one goal of the present study.
Both pathological and physiological types of CH are a con-
sequence of cardiomyocyte growth. As most of a cell’s dry
mass is protein, elevated protein synthesis plays a central role
in cell growth (9), and mTORC1 is a key positive regulator of
protein synthesis and cell growth. Activation of mTORC1 was
observed in exercise-induced (10) cardiac hypertrophy. Sim-
ilarly, in TAC mice, mTORC1 is initially rapidly activated, but
subsequently inactivated. Indeed, administration of the
mTORC1-specific inhibitor rapamycin prior to or after TAC
can attenuate or reverse TAC-induced hypertrophy and heart
dysfunction in mice (11, 12). Given the distinct signaling path-
ways activated -adrenergic stimulation and insulin in ARVC,
and their roles in cardiac hypertrophy, it was therefore impor-
tant to compare the impact on the synthesis of specific pro-
teins in ARVC.
mTORC1 plays important roles in regulating protein synthe-
sis in isolated adult rat ventricular cardiomyocytes (ARVC).
Indeed, activating mTORC1 by over-expressing a small
GTPase, Rheb, which positively regulates mTORC1 (13), is
sufficient to drive rapid and marked growth of ARVC (14). PE
substantially enhances global protein synthesis and ARVC
growth, which is largely blocked by rapamycin (14), again
indicating that mTORC1 signaling is important for CH. Insulin
also stimulates protein synthesis in an mTORC1-dependent
manner in ARVC (15).
This study aims to address several key questions: which
specific proteins’ synthesis is increased in response to differ-
ent hypertrophic stimuli? Are those proteins also altered in
pathological and physiological animal models? Are changes
in the synthesis of specific proteins exerted at the level of
transcription or translation? Does mTORC1 signaling play a
role in regulating the translation of specific mRNAs?
To address these questions, we optimized a recently de-
veloped method wherein stable-isotope labeled amino acids
are used to tag newly synthesized proteins (pulsed SILAC;
pSILAC). Such a pSILAC approach was used to study the
regulation of protein accumulation rates by mTOR signaling in
HeLa cells (16), a rapidly dividing cancer cell line, which
synthesizes proteins at a much higher rate than primary cells
such as ARVC. We subsequently improved the pSILAC ap-
proach to enhance its selectivity and sensitivity for the anal-
ysis of newly synthesized proteins by combining it with
azidohomoalanine (AHA) labeling/click-chemistry and subse-
quent bottom-up LC-MS proteomic analysis (Fig. 1) (17). Dur-
ing incubation in cell culture, AHA (an analog of methionine)
becomes incorporated into, and covalently tags, newly syn-
thesized proteins. The resulting azide-derivatized proteins can
then be selectively coupled and enriched to biotin-alkyne
beads for visualization using fluorescently labeled streptavi-
din. Alternatively, the azide-derivatized proteins are selec-
tively isolated and enriched with alkyne-functionalized aga-
rose beads and subjected to trypsin proteolysis followed by
liquid chromatography-mass spectrometry (LC-MS/MS). The
collective analytical attributes of this proteomics approach,
referred to as quantitative noncanonical amino acid tagging
(QuaNCAT), permits the sensitive and selective measurement
L-azidohomoalanine; ALDOA, Aldolase A; ARVC, Adult rat ventricular
cardiomyocytes; CDS, Coding DNA sequence; FDR, False discovery
rate; hnRNPs, Heterogeneous nuclear RNA-binding proteins; HSP60,
Heat shock 60kDa protein 1; IGF1, Insulin-like growth factor 1; Lmod,
Leiomodin; MDH2, Malate dehydrogenase 2; mTORC1, mammalian
target of rapamycin complex 1; NRAP, Nebulin-related anchoring pro-
tein; PE, Phenylephrine; QuaNCAT, Quantitative Noncanonical Amino
acid Tagging; pSILAC, pulsed stable isotope-labeling with amino acids
in cell culture; PTBP1, Polypyrimidine tract-binding protein 1; RPs,
Ribosomal proteins; S6Ks, S6 kinases; TAC, Transverse aortic constric-
tion; TOP, Terminal oligopyrimidine tract.
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of the synthesis rates of specific proteins in cells (18, 19).
Other quantitative proteomic approaches that rely on the use
of label-free and isobaric stable isotope labeling to examine
the differential expression of proteins in hypertrophic or dis-
eased heart (20–22) only capture relative steady-state protein
concentration levels rather than assessing rates of de novo
synthesis. They are thus unsuitable for addressing the aims of
the current study. We have further optimized and applied the
QuaNCAT approach to measure the regulated synthesis of spe-
cific proteins in ARVC cells observed to occur at a very low rate.
Our results revealed several key new features in the re-
sponse of cardiomyocytes to hypertrophic stimuli. These in-
clude: (1) both insulin and PE increased the protein synthesis
rate to a similar set of proteins. Additionally, marked differ-
ences were observed in the patterns of induction of metabolic
enzymes and other proteins in response to PE and insulin; (2)
increased synthesis of pyruvate kinase M2, a protein involved
in anabolic remodeling of cellular metabolism, which may also
represent a new early marker for cardiac hypertrophy; (3) the
widespread importance of increased translation (rather than
transcription) in the rapid effects of hypertrophic agents; and
(4) a key role for mTORC1 signaling in the effects of hyper-
trophic agents of the translation of specific mRNAs, including
many mRNAs that are not members of the subset of TOP
(terminal oligo-pyrimidine) mRNAs, which are translationally
regulated by mTORC1.
EXPERIMENTAL PROCEDURES
Experimental Design and Statistical Rationale—ARVCs derived
from wild-type Sprague-Dawley male rats were treated with phenyl-
FIG. 1. Scheme of method combin-
ing pSILAC with AHA labeling. See
Experimental Procedures for further
information.
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ephrine (10 mol/L), insulin (100 nmol/L), and rapamycin (100 nmol/L).
AHA-pSILAC was combined with mass spectrometry to identify newly
synthesized proteins as a result of each treatment. Replicate exper-
iments were performed, three in the case of insulin and four for
phenylephrine.
Identified proteins were validated in ARVCs using two similar but
independent methods. We determined the total mRNA levels of se-
lected candidate proteins, to examine whether increased synthesis of
these proteins reflects increased translation of their mRNAs or in-
creased mRNA levels.
To test the role of mTORC1 signaling in regulating the synthesis of
specific proteins in ARVCs, we repeated the AHA-pSILAC labeling
experiments using ARVCs that were treated with PE or insulin in the
presence of the mTORC1 inhibitor rapamycin. Finally, key proteomic
results were studied using in vivo rodent models of pathologic and
physiologic cardiac hypertrophy. Data from independent experimen-
tal replicates were analyzed using Student’s t test, Significance was
set to p  0.05.
Rats—Animals used for isolating ARVC were wild-type Sprague-
Dawley male rats from Charles River, Oxford, UK. Animals were
reared and sacrificed in line with the United Kingdom Animals (Sci-
entific Procedures) Act, 1986. The method of sacrifice employed here
was cervical dislocation according to the UK Home Office regulations
Schedule 1. Animals used in the TAC study were as described earlier
(23).
Isolation of Adult Rat Ventricular Cardiomyocytes—Isolation and
maintenance of adult rat ventricular cardiomyocytes (ARVC) were
described earlier (15, 24). ARVC were treated with following com-
pounds at the indicated concentrations: phenylephrine (10 mol/L),
insulin (100 nmol/L), and rapamycin (100 nmol/L).
pSILAC and Click-It Chemistry Using Invitrogen Alkyne Agarose
Resin Beads—ARVCs were cultured in complete M199 medium
(M199 medium containing 5.55 mmol/L glucose, 0.68 mmol/L gluta-
mine, 5 mmol/L creatine, 2 mmol/L-carnitine, and 5 mmol/L taurine)
after isolation; 30 min prior to any treatments, ARVCs were trans-
ferred into Customized M199 media (Dundee Cell Products, Dundee,
Scotland) containing 0.41 mmol/L heavy lysine and 0.71 mmol/L
heavy arginine, or 0.41 mmol/L medium lysine and 0.71 mmol/L
medium arginine. Both media contain low levels of methionine (25.13
mol/L, about 25% of that in the standard M199 medium). After 30
min, ARVCs were treated with various inhibitors in the presence of 2
mmol/L azidohomoalanine (AHA). Forty-eight hours later, cells were
washed twice with cold PBS and lysed in pSILAC lysis buffer (8 mol/L
urea, 300 mmol/L Tris-HCl pH 8, 4% (w/v) CHAPS, 1 mol/L NaCI)
containing proteinase inhibitors. 400 g of lysate from the control and
treatment animals were mixed together. The mixed protein lysates
were reacted with alkyne agarose resin beads. The click reactions
were conducted according to the manufacturer’s instructions Life
Technologies KIT C-10416 Life Technologies, Loughborough, UK,
after which, the newly synthesized proteins were covalently conju-
gated to the alkyne-agarose resin beads. They were then digested
using 0.1 g Lys-C for 4 h, followed by trypsin digestion (0.1 g/l X
1 l 37 °C overnight) and subjected to mass spectrometry analysis, as
reported by the authors (17). Replicate experiments were performed,
three in the case of insulin and four for PE. This procedure is sum-
marized in Fig. 1.
Liquid Chromatography-Mass Spectrometry analysis—Peptide
mixtures were de-salted with 100 l capacity C18 tips (Thermo Sci-
entific) with five incremental iterations from 2 to 98% HPLC grade
acetonitrile (Fisher Scientific) in 0.1% analytical grade formic acid
(Fisher Scientific). Eluates were lyophilized to dryness and reconsti-
tuted in 20 l of loading solution (2% acetonitrile, 0.5% formic acid).
A sample of volume 14 l was then injected onto a C18 -Precolumn
(300 m ID  10 mm L, 5 m particle; 100 Å pore size, Acclaim
PepMap100, Thermo Scientific) at 20 l/min for 6 min using the
loading solution as the mobile phase to trap and de-salt its peptide
content. The purified peptides were then loaded onto a high-capacity
nano-capillary reverse phase C18 column (75 m  50 cm, 2 m
particle; 100 Å pore size; Acclaim PepMap 100 column, Thermo-
Scientific) retrofitted to a PicoTip nESI emitter (New Objective,
Woburn, MA) and gradient separated as reported by the authors (17).
Nanospray ionization was conducted at 2.4 kV and ions were char-
acterized with an FT-Orbitrap Elite (Thermo Scientific) at 240,000
mass resolution. The top 12, 2 and 3 precursor ions per mass
spectrometry (MS) scan (minimum intensity 1000) were characterized
by high-energy collisional dissociation (HCD; 15,000 mass resolution,
1.2 Da isolation window, 40 keV collision energy) and collision-in-
duced dissociation (CID; ion trap MS, 2 Da isolation window, 35 keV)
with a dynamic exclusion (5 ppm) of 200 s.
MS Data Processing—Peptide spectrum matching and quantifica-
tions were performed with Proteome Discoverer 1.4 (Thermo Scien-
tific) with SequestHT against the UniprotKB SwissProt Rattus norve-
gicus proteome (downloaded 04/2014; 28861 entries). For matching
and quantitation, precursor tolerance was set at 10 and 3 ppm,
respectively. Fragment matching was set at 0.02 and 0.5 Da for HCD
and CID, respectively. Target-decoy searching allowed for 1 missed
cleavage, a minimum length of 6 residues and a maximum of three
variable (1 equal) modifications of Met-AHA (M), deamidation (Asn,
Gln), or phosphorylation (Ser, Thr, or Tyr). Carbamidomethyl (Cys)
was set as a fixed modification with Lys (4 Da), Arg (6 Da), and Lys
(8 Da), Arg (10 Da) searched to determine medium and heavy
labeled peptides, respectively. The false discovery rate (FDR) was
estimated with Percolator at 5% peptide FDR to enable parallel
protein grouping and quantitation. The mass spectrometric proteomic
data have been deposited to the ProteomeXchange Consortium (25)
via the PRIDE partner repository (26, 27) with the data set identifier
PXD004127.
Protein Hierarchical Clustering Analysis and MetaCore Pathway
Analysis—Heat-map construction of proteins analyzed in at least one
replicate of all four conditions (i.e. Ins versus control, PE versus
control, InsRapa versus Ins, PERapa versus PE) was generated
using Cluster 3.0 (http://bonsai.hgc.jp/mdehoon/software/cluster/
software.htm) and Java Treeview (http://jtreeview.sourceforge.net).
MetaCore (GeneGo, St. Joseph, MI) was applied to identify over-
represented biological processes and to identify direct protein inter-
action networks of proteins of interest. FDR-corrected p values 
0.05 were considered significant.
pSILAC Plus Click Chemistry Using Invitrogen Alkyne Biotin—
ARVCs were cultured and treated as described above, and then lysed
in cell lysis buffer (1% Triton® X100, 50 mmol/L -glycerophosphate,
1 mmol/L EDTA, 1 mmol/L EGTA, 0.5 mmol/L Na3VO4, 1 mmol/L-
dithiothreitol, and proteinase inhibitor mixture; Roche, catalog num-
ber 11873580001). Protein concentrations were determined by Brad-
ford assay. Fifty to 200 g newly synthesized proteins were reacted
with biotin-alkyne, according to the procedure described in detail in
the manufacturer’s instructions (Life Technologies: C-10276). Forty
microliters of click reaction products were subjected to SDS-PAGE,
then transferred onto a nitrocellulose microporous membrane, which
was blocked with 5% (w/v) fat-free powdered milk in PBS-0.02% (v/v)
Tween. After three washes with PBS-0.02% (v/v) Tween, the mem-
brane was incubated with streptavidin, Alexa Fluor® 680 (1:10,000
dilution; 45 min) and, after another three washes, the membrane was
scanned using the Odyssey® Infrared Imaging System.
5-RACE (Rapid Amplification of cDNA Ends)—One g of total RNA
from rat heart and a gene-specific primer were used to generate the
first strand cDNA containing the 5-UTR and part of the coding region
of mRNA, then use RNase H to degrade the mRNA template. After-
ward, the first-strand cDNA was ligated with the DNA oligo linker by
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T4 RNA ligase. The sequence of this DNA oligo is 5-CGTTTGCGAG-
CAGCGTGGCA-3, the 5-end of the oligo is phosphorylated, and its
3-OH is blocked to eliminate self-ligation of the linker. Thus, the
unknown 5-UTR can be amplified by primer pairs complementary to
the linker and the coding sequence region. In order to achieve better
amplification efficiency, nested PCR (two rounds of PCR with different
reverse primer) is required. The PCR product was purified using a gel
extraction kit and then sent for Sanger sequencing.
Measuring Specific Newly Synthesized Proteins by Click Reac-
tion—Isolated ARVC were cultured and treated with insulin/PE as
described above. AHA (2 mmol/L) was added into the medium im-
mediately after the treatment; 48 h later, cells were lysed, and endog-
enous ACO2 was immunoprecipitated (IP’d) from 250 g of total
lysate protein. IPs were divided into two equal portions; one was
analyzed by Western blot to verify the IP efficiency, whereas the other
as used for verification of the pSILAC data. IPs were subjected to
SDS-PAGE, proteins were transferred onto a nitrocellulose mem-
brane and the membrane was blocked with 5% (w/v) fat-free pow-
dered milk in PBS-0.02% (v/v) Tween. After three washes with PBS-
0.02% (v/v) Tween, the membrane was incubated with 1x reaction
buffer (prepared in accordance with the manual of Click-iT® Protein
Enrichment Kit, Life Technologies: C-10416) containing biotin-alkyne
overnight. After the click reaction, the reaction solution was dis-
carded, and the membrane was washed three times with PBS-0.02%
(v/v) Tween. Finally, the membrane was incubated with Streptavidin,
Alexa Fluor® 680 (1 in 20,000 dilution) for 45 min; after another three
washes, the membrane was scanned using the Odyssey® Infrared
Imaging System.
Cell Culture, Cell Lysis, Western Blotting, Immunoprecipitation,
Quantitative Real-Time PCR, and Measurement of Protein Synthesis
Rates—HEK293 cells were cultured in complete DMEM (Dulbecco’s
modified Eagle’s medium supplemented with 10% (v/v) fetal bovine
serum (FBS) and 2 mmol/L L-glutamine. Penicillin G and streptomycin
sulfate were also added to the medium to final concentrations of 100
units/ml and 100 g/ml, respectively). Other procedures have already
been described (28).
5-RACE primers used in this study are listed in supplemental Table
S1.
Measuring Newly Synthesized Specific Proteins by [35S]-Methio-
nine Labeling—Isolated ARVC were cultured and treated with insulin
or PE as described above, [35S]methionine (Perkin Elmer, Coventry,
UK; 10 Ci/ml) was added into the medium; 48 h later, cells were
lysed, and endogenous HSP60 was IP’d from 250 g total lysate. IP’s
were subjected to SDS-PAGE and Coomassie brilliant blue staining
and newly synthesized HSP60 in the dried gel was visualized by
autoradiography.
Protein Extraction from Tissues—All mouse or rat tissues (20 mg)
were frozen and were pulverized in liquid nitrogen with a mortar and
pestle, then lysed with 400 l RIPA buffer (50 mmol/L Tris HCl 7.4,
150 mmol/L NaCl, 1% Triton X-100 1% sodium deoxycholate, 0.1%
(w/v) SDS, and proteinase inhibitors (Roche, complete, EDTA-free
Protease Inhibitor Mixture; catalog number: 11873580001)). Protein
concentrations were determined by the BCA method.
RNA Extraction from Tissues—All mouse or rat tissues (20 mg)
were homogenized in liquid nitrogen with a mortar and pestle, then
lysed with 1 ml TRIzol®, the following steps of RNA extraction can be
found in manufacturer’s instructions (Life Technologies: 15596–018).
qPCR primers used in this study are listed in supplemental Table S2.
Rat 18S rRNA primers for qPCR were from Primerdesign, Southamp-
ton, UK.
Transverse Aortic Constriction (TAC)—Animals, surgical interven-
tions, clinical assessment, and echocardiographic confirmation of
cardiac hypertrophy were described as in (23) (total number of rats 
24).
Exercise-induced Cardiac Hypertrophy—Animals at 3 weeks of age
were randomly assigned to either the training or the control group
(sedentary). The rats in the training group were exercised on a tread-
mill over a period of 10 weeks with 16% incline, a speed of 25 m/min,
and four training episodes per week (Monday, Tuesday, Thursday,
and Friday). Running times were incrementally increased as follows:
30 min/d in the first week, 45 min/d in the second week, 60 min/d in
the third, 75 min/d in the fourth week, 90 min/d in the fifth week, 105
min/d in the sixth week, and 120 min/d in the last 4 weeks. After 2 and
6 weeks and at the end of the training protocol, animals were ana-
lyzed for echocardiographic and in vitro examination. As reported
earlier, this training regime induces cardiac growth, manifested as an
increased heart weight/body weight ratio and other parameters as-
sociated with CH (29).
Experiment with Pregnant Mice—C57Bl6/J mice (females were 4
months of age at the time of euthanization; males were 2–6 months of
age at time of mating) were mated and females were checked for
plugs daily (total mice number  38). Once they had plugged, female
mice were removed to a separate cage; this was considered day 1 of
pregnancy. Control mice comprised female mice that plugged but
were not pregnant or equivalently aged mice that had not been
mated. Mice were euthanized by cervical dislocation at the indicated
times postinsemination and their hearts rapidly dissected out. All mice
were confirmed pregnant via dissection and visual inspection of the
uterus.
Determination of Cell Size—ARVC were seeded on laminin-coated
glass coverslips and treated with vehicle control or insulin (100
nmol/L) for 48 h. After treatment, cells were washed twice in phos-
phate buffered saline (PBS, 18912–014, Gibco) and then fixed in 4%
formaldehyde (F8775, Sigma-Aldrich) for 15 min. Fixed cells were
washed again thrice with PBS and then labeled with 1 Cellmask
stain (C10046, Life Technologies) and mounted in Prolong® Gold
Antifade Mountant (contains 4,6-diamidino-2-phenylindole (DAPI),
P36935, Life Technologies). Cells were visualized using Leica TCS
SP8X/MP microscope equipped with a tuneable white light laser
using a 40 oil immersion objective lens (NA  1.30) numerical
aperture objective. The cross-sectional area was estimated at the
center plane of the cell. Relative cell size was then determined using
the Leica Application Suite X (LAS X) software (version 1.1.0.12420).
Statistical Analysis—Data from independent experimental repli-
cates were analyzed using Student’s t test, Significance was set to
p  0.05.
RESULTS
Proteomics Methodology Optimization—ARVC do not di-
vide in culture and show low rates of protein synthesis (mea-
sured as [35S]methionine incorporation), which are only about
5% of the rates in HEK293 cells, a cell line that proliferates
rapidly in culture (Fig. 2A). Our preliminary data (not shown)
indicated that applying the pSILAC approach alone was un-
able to detect sufficient amounts of labeled peptides with
adequate sensitivity because of the masking and/or suppres-
sion effects of the highly abundant, nonlabeled background
signal from pre-existing proteins. Further investigation
showed that levels of ribosomal proteins and translation fac-
tors are low in normal rat heart compared with tissues that
maintain higher protein synthesis rates such as pancreas or
liver (Fig. 2B). The AHA-containing newly synthesized proteins
generated by our modified approach were captured with
90% efficiency by the alkyne agarose resin beads (Fig. 2C).
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FIG. 2. Optimization of pSILAC conditions. A, ARVC and HEK293 cells were maintained as described in methods; 30 min prior to adding
[35S]methionine. DMEM was replaced by M199 medium and some cells were treated with cycloheximide (35.54 mol/L) where indicated. 18 h
later, cells were lysed and analyzed for [35S]methionine incorporation as described in the Methods. B, Twelve different tissues from a single
rat were pulverised in liquid nitrogen, then lysed with RIPA buffer. Protein concentrations were measured by the BCA method and 20 g of
protein from each were subject to Western blots. C, HeLa cells and ARVC were labeled with AHA for 18 h. Cells were then lysed, and subjected
to the ‘click’ reaction, the alkyne carrier being alkyne-agarose resin. Corresponding amounts of input lysate and supernatant after click reaction
were clicked to alkyne-biotin and visualized by Streptavidin, Alexa Fluor® 680. D, ARVC were pre-incubated in M199 medium with different
concentrations of methionine (25%  25.13 mol/L, 50%  50.26 mol/L) for 30 min, AHA or normal methionine were then added into the
Translational Control by Hypertrophic Agents in Heart Cells
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To improve the efficiency of AHA labeling, we placed ARVC
in methionine-free medium; this increased the efficiency of
[35S]methionine incorporation 9-fold (data not shown). How-
ever, methionine itself, an essential amino acid, can regulate
mTORC1 signaling (30), so we needed to use methionine
concentrations that allowed better AHA incorporation effi-
ciency without affecting the mTORC1 signaling pathway. De-
creasing the concentration of unlabeled methionine in the
M199 medium from 50% to 25% of the standard one also
doubled the signal (Fig. 2D). Increasing the labeling time from
24 h to 48 h resulted in approximately a doubling of the
signals (Fig. 2D). Mass spectrometric data (not shown)
showed that 48 h labeling-time and a methionine concentra-
tion of 25.13 mol/L in M199 medium provide good condi-
tions to use for ARVC (and increased the number of proteins
identified at 24 h from 105 to 167, not shown).
ARVC are particularly challenging cells in which to study
protein synthesis because of their very low intrinsic rates of
protein synthesis (as documented in this report). This is true
whether one uses radiolabeled amino acids (which we have
utilized previously, e.g. (15)) or stable isotope labeling meth-
ods (as used here). In such primary cells, to “scale” this kind
of experiments to the desired objectives, [35S]methionine in-
corporation should be performed prior to experiments using
AHA labeling. If the rate of protein synthesis in the target cells
is similar to cells such as HeLa, 6 h pulse labeling is sufficient
to identify 300–400 proteins (16). On the other hand, if the
protein synthesis rate in the cells of interest were only 5%
compared with HeLa (as it is for ARVCs), then a substantially
longer time of labeling would be required (to identify a similar
number of proteins, it is theoretically necessary to use a
20-times longer time incubation period). In this case, we la-
beled for 48 h, the longest feasible time (because, as already
noted, ARVCs can only be maintained in culture for a limited
period). To help overcome this limitation, we combined pulsed
SILAC with AHA labeling to permit us to purify newly made
proteins and remove the un-labeled proteins that generate
peptides that coelute with, suppress, and mask the presence
of labeled proteotypic peptides of interest. For each biological
replicate, 0.9–1.2 million ARVCs were used.
To bypass the need to use offline liquid chromatographic
peptide purification and separation while preserving pro-
teome coverage, the peptides were on-line de-salted and
concentrated with a high-capacity C18 -Precolumn (300
m 10 mm, 5 m particle; 100 Å pore size) and then loaded
onto the 50-cm length reverse phase C18 ultraperformance
nano-capillary column as reported by the authors (17). Such
an on-line chromatographic configuration exhibited the satis-
factory loading capacity and separation efficiency needed to
cope with the 400 g total protein, which was injected for
each biological replicate run. This approach was, in part,
originally developed and applied by Thakur et al. (31) for the
deep and sensitive proteomic analysis of yeast cell lysates in
a single 8-h LC-MS analysis run.
Over 48 h, PE and insulin increased the overall protein
synthesis rates in ARVC roughly 1.5-fold and 1.9-fold (Fig.
2E), respectively, in line with our previous data (32). Moreover,
the intensities of all the visible radiolabeled bands were in-
creased by insulin and by PE (Fig. 2E). [35S]Methionine incor-
poration measures global changes in protein synthesis rates,
but cannot easily be used to study changes in the synthesis of
different protein species (Fig. 2E), whereas our new method
does readily allow us to identify and quantify changes in rates
of synthesis of specific proteins (Fig. 1).
PE and Insulin Each Increase the Synthesis of Many Pro-
teins in ARVC—Our previous work showed that 48 h PE
treatment promotes hypertrophic growth of ARVC in vitro. A
recent study showed that excessive activation of the insulin
signaling pathway contributes to the development of patho-
logic cardiac hypertrophy (8). In the present study, we meas-
ured the size of ARVC after insulin treatment (100 nM). The
data show that 48 h of insulin treatment significantly increases
the cells’ size (supplemental Fig. S1A, S1B). Insulin treatment
increased the levels of expression of the hypertrophy-associ-
ated genes for ANF and BNP (supplemental Fig. S1C). Our
data support the conclusion that high-dose insulin treatment
causes hypertrophic growth of ARVC that resembles more the
pathological type. However, insulin does elicit different re-
sponses from PE; for example, PE activates the MEK-ERK
signaling pathway, which has been shown to play an impor-
tant role in overload-induced CH (15, 33, 34). On the other
hand, insulin activates the PI3K-AKT-mTORC1 signaling
pathway (15).
The LC-MS data (supplemental Tables S3–S17) show that
treatment with PE or insulin increases the synthesis of various
categories of proteins including enzymes of glycolysis, the
Krebs cycle and fatty acid -oxidation as well as proteins
involved in the cytoskeleton and the contractile machinery.
Consistent with the fact that both stimuli cause growth of
ARVC and are involved in cardiac hypertrophy in vivo, there is
medium immediately after treatment, After different time periods as indicated, cells were lysed, the same amount of total proteins from each
group were subjected to click reaction. The alkyne carrier here is biotin-alkyne. After Click reaction, 40 l of reaction product were analyzed
by SDS-PAGE followed by Streptavidin, Alexa Fluor® 680 visualization. The bar graph shows quantification for newly synthesized protein
minus negative control (lane 3). E, ARVC were incubated in M199 medium with low concentration of methionine (25.13 mol/L) for 30 min.
Some were then stimulated by insulin or PE as indicated and [35S]methionine was added to the medium immediately. 48 h later, cells were lysed
and 20 g of total protein were subjected to SDS-PAGE and Coomassie blue staining, whereas newly synthesized proteins in the dried gel were
visualized by autoradiography. The bar graph shows quantification for newly synthesized protein:total protein from three independent
experiments. Significance was determined by Student’s t test.
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considerable qualitative overlap between the sets of proteins,
which are up-regulated by the two stimuli. As a means to
verify the LC/MS/MS analysis efficiency, the signal response
to all proteotypic peptides listed in the reported proteins/
peptide lists gave an analytical confidence  95%. Close
inspection of the precursor and product ion spectra of pro-
teotypic peptides exhibited satisfactory signal-to-noise ratios
with no appearance of low or saturated ion signal responses.
Furthermore, in silico Pathway Map analysis (using Meta-
Core), necessarily restricted only to those proteins identified
with an altered synthesis rate (Fig. 3A, supplemental Tables
S3 and S18), against the entire rat genome confirmed that
glycolysis and gluconeogenesis (FDR (False Discovery Rate)-
corrected p value  4.4e-5), mitochondrial long chain fatty
acid -oxidation (FDR-corrected p value  7.7e-5), muscle
contraction/GPCRs in the regulation of smooth muscle tone
(FDR-corrected p value  4.1e-3), and muscle contraction/
regulation of eNOS activity in cardiomyocytes (FDR-corrected
p value  1.3e-2), were significantly over-represented biolog-
ical processes. We recognize that this analysis is limited by
the fact that even this enhanced QuanCAT method cannot
identify and quantify all the proteins whose synthesis rates is
changed.
Insulin and PE promote the synthesis rates of similar sets of
proteins. However, for some proteins the effect of insulin is
stronger than PE, for example, insulin increases the synthesis
rate of Atp5a1 to 504% and PE increases the synthesis rate of
Atp5a1 only to 139%, so the effect of Insulin in the synthesis
of atp5a1 is much stronger than PE, then we list top ten
proteins in this category whose synthesis was more strongly
increased by insulin than by PE (Fig. 3B). The data are plotted
as (change in synthesis caused by insulin- change caused by
PE)/change caused by PE as a percentage. Those proteins
are linked to the biological functions energy metabolism (7
proteins), the cytoskeleton (1 protein), or mRNA translation (2
proteins). All these functions appear relevant for the healthy
growth of ARVC, e.g. during compensated hypertrophy. A
direct interaction network of all proteins whose synthesis was
found to be differentially regulated after PE or insulin treat-
ment illustrates which of these proteins are functionally inter-
linked (positive or negative regulation, Fig. 4).
Three important points emerge from the data in supplemen-
tal Table S3 and the first two columns of Fig. 3A. First, insulin
and PE each increase the synthesis of almost all the identified
proteins. Interestingly, in almost all cases, insulin increases
the synthesis of individual proteins more than PE in line with
its greater effect on overall protein synthesis (Fig. 2E). Sec-
ond, the effect of insulin on synthesis of certain metabolic
enzymes is greater than its effect on general protein synthe-
sis. Third, the quantitative differences between insulin and PE
differ across most protein categories, some being increased
by insulin much more than others, relative to PE, e.g. Dld
(dihydrolipoamide dehydrogenase, required for mitochondrial
energy metabolism), Etfa (electron transfer flavoprotein,
-polypeptide, mediates the initial step in mitochondrial oxi-
dation of fatty acids), GAPDH (now known to catalyze a lim-
iting step in glycolysis, (2)) and Atp5a1 (a subunit of the
mitochondrial ATP synthase) (Fig. 3B). Indeed, seven of the
top ten proteins in this group are enzymes involved in energy
metabolism, i.e. the Krebs cycle, glycolysis or -oxidation. In
particular, GAPDH, which is now known to be the regulatory
enzyme of glycolysis under aerobic conditions (35), was much
more strongly increased by insulin than by PE (Fig. 3A, 3B).
These changes likely promote a more robust and resilient
metabolic profile in insulin-induced hypertrophy. In contrast,
the differences between the effects of PE and insulin on
synthesis rates are almost nonexistent for most heat shock
proteins and less pronounced for many cytoskeletal compo-
nents (supplemental Tables S3–S17). These quantitative dif-
ferences for different proteins indicate the existence of clear
differences between the effects of the two stimuli studied on
the synthesis of specific proteins, rather than simply differ-
ences in the magnitude of their effects on all proteins across
the board. Our data suggest that rapidly after hypertrophic
stimulation, the synthesis rates of many metabolic enzymes
are increased, likely to support the increased demand for
energy. This could help to explain increased cardiac perfor-
mance in the compensation stage shortly after pressure over-
load. The quantitative differences between the rapid effects of
insulin and PE in cultured ARVC presumably reflect intrinsic
differences between these two stimuli rather than differences
because of cardiac morphology or overall metabolism.
Validation of Altered Synthesis of Candidate Proteins—To
validate increased rates of synthesis of specific proteins, we
first employed the “traditional” method of [35S]methionine
labeling, followed by IP with a specific antibody and autora-
diography. This method depends upon having an antibody
that works well in IP. We tested 10 different antibodies
against various candidate proteins, and found, for example,
that an HSP60 (heat shock 60 kDa protein 1) antibody was
suitable. Our data show that the accumulation rates of HSP60
are indeed increased by insulin and PE in ARVC (Fig. 5A).
However, the total levels of HSP60 were not changed by 48 h
of insulin or PE treatment (Fig. 5C), likely because ARVC
already contain appreciable amounts HSP60 so the in-
creased rate of synthesis over 48 h does not discernibly
affect its total levels. In vivo, CH occurs over a longer time
period, over which levels of these proteins may indeed
change significantly.
AHA labeling provides a nonradioactive alternative to
[35S]methionine incorporation for assessing changes in the
synthesis rates of individual proteins. A strategy comprising
AHA labeling, IP with a specific antibody and “clicking” to
biotin followed by visualization using fluorescently labeled
streptavidin can thus be used to validate the accumulation
rate of candidate proteins (supplemental Fig. S2). Using this
new method, we found that the accumulation rate of ACO2
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(aconitase 2), a mitochondrial protein involved in the Krebs
cycle, was increased by insulin or PE (Fig. 5B).
If some candidate proteins have low initial levels and/or the
accumulation rate is very high, one may see a change in total
protein levels even after only 48 h. We did indeed observe
that, after 48 h labeling, the total level of desmin (as assessed
by Western blot) was increased by both insulin and PE. Insulin
also modestly but consistently up-regulated the total protein
FIG. 3. Hierarchical clustering analysis in heat map format of analyzed proteins. A, Insulin and PE increase the synthesis of a range of
proteins via the mTORC1 pathway, as their synthesis is inhibited by rapamycin. The molecular function gene ontology of these proteins were
manually curated with ExPASy bioinformatics resource portal (http://www.expasy.org) and mapped to glycolysis, energy and metabolism, fatty
acids beta-oxidation, amino acid metabolism, ATP synthesis, translation factors, cytoskeleton/sarcomere proteins, heat shock proteins or
other/unclassified proteins. B, The ten proteins whose synthesis is increased most strongly by insulin in comparison to PE. The data are plotted
as (change in synthesis caused by insulin- change caused by PE)/change caused by PE as a percentage.
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levels of PKM2 and eEF2 (Fig. 5C). In heart, the dominant
pyruvate kinase isoform is normally PKM1 (36). PKM1 and
PKM2 are encoded by distinct mRNAs derived from the same
transcript by alternative splicing, which involves polypyrimi-
dine-binding protein 1 (PTBP1), hnRNPA1 and hnRNPA2. The
protein levels of PKM1 and PTBP1 in ARVC were not changed
after insulin treatment (supplemental Fig. S3A).
The translation elongation factor eEF2 is encoded by a TOP
mRNA; such mRNAs contain, immediately adjacent to the
5-terminal cap structure, a terminal tract of oligopyrimidines
FIG. 4. A, Direct Protein Interaction Network (PIN) in silico analysis of all differentially expressed proteins after insulin and PE activation (B)
PIN in silico analysis of all differentially expressed proteins after insulin  rapamycin and PE  rapamycin activation. PIN analysis was
performed with MetaCore and curated with DAVID gene ontologies of subcellular localization. The analyzed proteins are color-coded as red
and blue, indicating their up- or down-regulation, respectively. The red, blue and gray lines denote a positive, negative or unspecified
regulation, respectively.
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FIG. 5. Validation of pSILAC results in ARVC. A, ARVC were starved in M199 medium containing low methionine (25.13 mol/L) for 30 min.
Cells were then stimulated with insulin or PE as indicated. [35S]methionine was added into the medium immediately after treatment and, 48 h
later, cells were lysed and HSP60 was IP’d from 250 g total lysate. IPs were subjected to SDS-PAGE and Coomassie brilliant blue staining,
whereas newly synthesized HSP60 in the dried gel was visualized by autoradiography. B, ARVC were treated and lysed as in panel A.
Endogenous ACO2 was then IP’d from 250 g of cell lysate. IP’s were divided into two equal portions; one was analyzed by Western blot to
verify the IP efficiency, whereas the other was used for verification of pSILAC result by Click reaction as described in Methods. C, ARVC were
isolated and maintained as described in Methods. Cells were transferred to low-methionine medium (25.13 mol/L) 30 min prior to treatment.
ARVC were treated with PE or insulin where indicated. Normal methionine or AHA was added into the medium immediately after treatment;
48 h later, cells were lysed and the same amounts of total protein were subjected to Western blots. D, ARVC were isolated, maintained and
treated as in panel C, 48 h later, cells were lysed, total RNA was extracted and subjected to RT-qPCR for the Aco2, Hspd1, Mb, Desmin, and
Acadl mRNAs. E, Summary depiction of changes in protein synthesis rates and mRNA levels of selected candidate genes. F, 5-UTRs of the
Desmin, Aldoa, and Jup mRNAs.
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(TOP) that confers control by mTORC1. mTORC1 promotes
the translation of TOP mRNAs. In ARVC, early studies re-
vealed that cardiac hypertrophy is accompanied by increased
ribosome levels in the myocardium (37). We used Western
blot analysis to examine another protein that was detected in
the proteomic analysis, and is encoded by a TOP mRNA (38),
i.e. eEF1G, part of the complex that regulates elongation
factor eEF1A (39) (supplemental Table S3). We found that the
level of eEF1G protein was also up-regulated by insulin in
ARVC (Fig. 5C). Up-regulation of elongation factors by
mTORC1 likely contributes to longer-term mass accumulation
during cardiac hypertrophy by increasing the cellular capacity
for protein synthesis. Levels of the small ribosomal subunit
protein S6, encoded by another TOP mRNA, were also slightly
increased by insulin (Fig. 5C).
Increased Synthesis of Specific Proteins Reflects Increased
Translation of Their mRNAs, Not Increased mRNA Levels—
Increased synthesis of a given protein could reflect enhanced
translation of similar levels of mRNA or, especially after peri-
ods as long as 48 h (the labeling time used here), higher
mRNA levels because of enhanced gene transcription. We
therefore also determined, by RT-qPCR, the total mRNA lev-
els of selected candidate proteins: ACO2, HSP60, myoglobin,
desmin, and an acyl-coenzyme A dehydrogenase (Acadl).
Their mRNA levels were either unchanged or rose much less
than the rates of synthesis of the corresponding proteins (Fig.
5D, 5E). For example, although desmin mRNA levels in-
creased in response to insulin or PE, this effect was much
smaller (1.2- or 1.5-fold) than the 8- or 3-fold changes in the
synthesis of desmin itself (Fig. 5E). Thus, insulin and PE
regulate the synthesis of these proteins primarily by increas-
ing the translation of their mRNAs.
PE and Insulin Activates Synthesis of Specific Proteins in
ARVC via mTORC1—As noted, both PE and insulin activate
mTORC1 signaling in ARVC (15, 33, 34), and mTORC1 also
plays a key role in cardiac hypertrophy (11, 12, 40, 41). To test
the role of mTORC1 signaling in regulating the synthesis of
specific proteins in ARVC, we repeated the AHA-pSILAC la-
beling experiments using ARVC that were treated with PE or
insulin in the presence of the mTORC1 inhibitor rapamycin
(RAPA). Hierarchical clustering analysis, presented in heat-
map format (Fig. 3A), revealed distinct ARVC proteome ex-
pression profiles for insulin over control and PE over control
relative to the insulin  rapamycin over insulin and PE 
rapamycin over PE data sets. Interestingly, rapamycin de-
creased the synthesis rate of almost every protein observed
(Fig. 3A, supplemental Tables S18–S30). The direct protein
interaction network analysis performed for all differentially
expressed proteins after insulin/PE treatment versus control
and insulin/PE Rapa treatment versus control, shows that a
number of those proteins are functionally interlinked (positive
or negative regulation, Fig. 4A and 4B).
For insulin, rapamycin generally decreased rates of synthe-
sis by 45–60%. The greatest inhibition (by almost 75%) was
seen for eEF2, which is encoded by a TOP mRNA. Rapamycin
also strongly inhibited the synthesis of GAPDH, as reported to
be controlled by mTORC1 in HeLa cells by the authors (16),
and desmin, which showed the greatest increase in response
to insulin. Rapamycin also inhibited the PE-induced increases
in the synthesis of every protein, but to a lesser extent (typi-
cally by 35–50%) than insulin, in line with the fact that PE also
stimulates synthesis of these proteins less than insulin. Again,
the strongest effect was observed for eEF2, a protein en-
coded by a TOP mRNA. These data indicate that increased
synthesis of all these proteins is promoted by mTORC1 sig-
naling, in line with our earlier observation that mTORC1 plays
a substantial role in the control of protein synthesis by PE or
insulin in ARVC (32).
Determination of the 5-UTR of Candidate mRNAs—Given
mTORC1’s major role in regulating synthesis of many proteins
at the translational level in ARVC and that mTORC1 promotes
translation of TOP mRNAs (42), it was of interest to determine
the sequence of the 5-UTRs of selected candidates. We
therefore employed a method that is based on a previously
published approach (43). Using this method (supplemental
Fig. S4), we determined the sequence of the 5-UTRs of the
mRNAs encoding desmin, ALDOA (aldolase A) and JUP (junc-
tion plakoglobin) in ARVC (supplemental Fig. S5, Fig. 5F).
These are not TOP mRNAs and do not possess the pyrimi-
dine-rich translational element previously reported to play a
role in mTORC1-mediated translational control (44). Their 5-
UTRs are actually short and unstructured, so they do not
resemble the types of structured mRNAs thought to be con-
trolled by the mTORC1-regulated eIF4F complex. Interest-
ingly, we have previously shown that PE regulates protein
synthesis in ARVC by mechanisms that depend on mTORC1
but in an eIF4F-independent manner (45).
PKM2, and eEF1G are Up-regulated in TAC Induced Hy-
pertrophy, But Not in Physiological CH Models—TAC (trans-
verse aortic constriction) is a classic model of pathological
cardiac hypertrophy caused by pressure overload, and in-
duces increased heart size (relative to body weight and other
hallmarks of CH (46). TAC induces activation of mTORC1 (11,
47), which is important in mass accumulation following TAC.
Our data show that, 2 weeks after TAC, three out of six rats
still exhibited very high levels of mTORC1 signaling (rpS6
p240/244 phosphorylation) (Fig. 6A), so it was of interest to
study whether candidate proteins identified by pSILAC were
also up-regulated in the TAC-rat model.
Expression of PKM2 was elevated following TAC at the
6-week time point (Fig. 6A–6C), indicating that PKM2 may
play important roles in this setting. Expression of eEF1G is
up-regulated in the TAC model at both 2- and 6-week time-
points. Increased expression of translation factors in the TAC
model likely helps support the faster protein synthesis that
leads to mass accumulation during cardiac hypertrophy. The
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FIG. 6. Expression of PKM2 and eEF1G is up-regulated in TAC animal model. A, B, TAC operation was as described in EXPERIMENTAL
PROCEDURES. At two- and six-week time points, six experimental rats and six age-paired controls were sacrificed; left ventricles were
pulverised in liquid nitrogen, then lysed with RIPA buffer, and protein concentration was measured by the BCA method. 20 g of protein from
each heart was subjected to Western blots. C, Quantification of PKM2 and eEF1G from panels A, B. D, E, Control and TAC rats were as
described in panel A (six in each group). At two- and six-week time points, six experimental rats and six age-paired controls were sacrificed.
Total RNA was extracted from the left ventricles by TRIzol and analyzed by RT-qPCR.
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mRNA levels for eEF1G in TAC samples were not changed
(Fig. 6D, 6E), indicating its up-regulation is at a translational
level. The mRNA for desmin was slightly up-regulated (20%);
however, desmin protein levels in TAC samples were unal-
tered, which differs from what was observed in ARVC in
culture. Using two-dimensional electrophoresis (2-DE) and
mass spectrometry, it was found that, at 48 weeks, when left
ventricular hypertrophy is established, desmin protein levels
are up-regulated (48). In order to assess whether PKM2 and
eEF1G were also up-regulated in physiological cardiac hyper-
trophy model, we used Western blot analysis samples from in
exercise-induced CH heart (rat), and hearts from pregnant
mice, because two independent studies did not see CH in
pregnant rats, even though cardiac function was clearly en-
hanced (49, 50). Our data show that PKM2 and eEF1G were
not up-regulated in those two models (supplemental Fig. S6),
indicating PKM2 and eEF1G were specifically up-regulated in
pathological CH. Interestingly, a recent study reported that
PKM2 is also up-regulated in the heart of mice treated with
sunitinib, an anti-cancer drug whose use is associated with
heart failure (51). We found that protein levels of PKM1 and
PTBP1 in TAC samples were not changed (supplemental Fig.
S3B, S3C).
Chronic Activation of mTORC1 in MEFs Up-regulates the
Expression of Candidate Proteins—For candidate proteins
whose synthesis is regulated by mTORC1 signaling in ARVC,
chronic activation of mTORC1 is expected to upregulate their
total levels. Because loss of TSC2, a negative regulator of
mTORC1, leads to constitutive activation of mTORC1 (52), we
determined the total protein and mRNA levels for several
candidates in wild-type and TSC2	/	 MEFs (Fig. 7). This will
tell us whether the candidates identified in ARVC are heart
cell-specific or universal.
The results clearly show that the protein levels of ALDOA,
ACO2, JUP, and MDH2 are elevated in TSC2	/	 MEFs com-
pared with wild-type MEFs, especially for JUP, which was not
detectable in wild type MEFs, but expressed at substantial
levels in TSC2	/	 MEFs (Fig. 7A). The Jup mRNA level was
also increased by almost 4-fold in TSC2	/	MEFs. The mRNA
for ALDOA was not affected by activation of mTORC1, but its
protein levels in TSC2	/	MEFs are about 2.3-fold higher than
in wild-type MEFs (Fig. 7B, 7C). These results indicate that
mTORC1 regulates the expression of ALDOA at the transla-
tional level. In MEFs, expression of MDH2 and ACO2 were
also up-regulated by mTORC1, but are probably regulated at
the transcriptional level in MEFs, which differs from the situ-
ation observed in ARVC (Fig. 5E).
DISCUSSION
Here, we report the further optimization, refinement and
novel application of a recently developed QuaNCAT proteom-
ics approach (19, 53) to analyze the synthesis rates of specific
proteins in response to stimulation of ARVC with pro-hyper-
trophic agents. This approach provides an unbiased and ef-
fective means to quantify changes in the synthesis of many
proteins in parallel, even in cells with low ongoing rates of
protein synthesis. We have also developed a new and effec-
tive method for validating changes in the synthesis of specific
proteins identified using this approach. Both of these ap-
proaches will be valuable for studying changes in the synthe-
sis of specific proteins in a wide range of cell-types and
conditions.
Our QuaNCAT proteomics data reveal that, in response to
hypertrophic stimulation, the synthesis rates of many proteins
increase markedly even over the first 48 h. Insulin and PE
each increase the synthesis of a wide range of proteins.
According to the prior literature, the total levels of some of
these proteins are also up-regulated at later stages of path-
ological CH, e.g. the sarco/endoplasmic reticulum Ca2-
FIG. 7. Chronic activation of mTORC1 in MEFs increases the
expression of JUP, ADLOA, ACO2, and MDH2 proteins. Wild-type
and TSC2	/	 MEFs were cultured in complete DMEM. A, After lysis,
20 g of total protein were subjected to Western blot using the
indicated antibodies. B, After lysis, total RNA was extracted and
subjected to RT-qPCR analysis for Mdh2, Jup, Aco2, Aldoa, Hspd1,
and Rps6. C, Quantification and summary table of panels A and B.
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ATPase, GAPDH, myoglobin, mitochondrial elongation factor
EF-Tu (Tufm), 2-oxoglutarate dehydrogenase and phospho-
glycerate kinase, JUP (Junction Plakoglobin), VCL (Vinculin),
HSP90aa1, HSP90ab1, Ddx5, eEF1A1, eEF2 (54), filamin-C
(34, 54), and ENO1 (20, 54). The accordance between the
current study and previous ones demonstrates the validity of
our newly developed method. Our data also show the ele-
vated synthesis of those proteins in CH is mediated primarily
at the level of the increased translation of their mRNAs driven
by mTORC1 signaling. Thus, activation of the synthesis of
specific proteins is a very rapid translational response to
hypertrophic simulation of ARVC, which precedes the long-
established but slower increase in their translational capacity
(ribosomal content) (2).
Our data also show that PE and insulin promote the syn-
thesis of generally similar sets of proteins. However, on aver-
age, the increase in their rates of synthesis was 102% greater
for insulin than PE. For certain specific proteins, the relative
rate of stimulation between the insulin and PE was found to be
even larger (Fig. 3A); namely, among the top ten proteins in
this category, seven were metabolic enzymes, and only one
was a structural cytoskeletal protein. The differential increase
in the rate of synthesis of these two groups of proteins is likely
to give rise to different metabolic outcomes in the two types of
settings, because insulin more strongly enhances the expres-
sion of proteins involved in supplying metabolic energy, which
is required for enhanced cardiac function.
As stated, GAPDH is known to be a rate-limiting enzyme for
aerobic glycolysis (35). Another essential participant to aero-
bic glycolysis is pyruvate kinase, which catalyzes the trans-
formation of phosphoenolpyruvate into pyruvate and exists as
four isoforms, PKL, PKR, PKM1, and PKM2. In adult animals,
the dominant form of PK in heart is PKM1 (36). Given the role
of PKM2 in regulating the channeling of carbon atoms into
biosynthesis or oxidation (55), the ability of PE and especially
insulin to increase the synthesis of GAPDH and PKM2 is of
particular interest. Interestingly, we found that the synthesis of
PKM2 is up-regulated by PE/insulin via mTORC1 signaling in
ARVC. The levels of PKM2 protein are also up-regulated in
hearts from animals subjected to TAC. The biological signifi-
cance of PKM2 is underscored by the observation that it plays
important roles in tumorigenesis (56). In various types of tu-
mors, pyruvate kinase expression shifts to the PKM2 isoform
(57). Cancer cells make use of anaerobic glycolysis (58) to
utilize glucose efficiently to generate biomass (the “Warburg
effect”), i.e. the synthesis of macromolecules required for cell
growth and division. PKM2 plays a key role in regulating the
direction of carbon atoms toward biosynthesis or oxidation
(55). In TAC rats, upregulating PKM2 likely also serves to
provide precursors for macromolecular synthesis to support
cardiomyocyte growth.
These changes suggest that the alterations in intermediary
metabolism induced by hypertrophic stimuli are similar to
those seen in cancer cells, where enhanced metabolic capac-
ity is also a key feature. Additionally, PKM2 is the isoform
initially expressed in embryonic tissues, so the increased
expression of PKM2 during TAC may reflect the recapitulation
of a fetal gene program. We used five pairs of qPCR primers
to try to measure Pkm1 and Pkm2mRNA levels in ARVC or rat
hearts, but unfortunately, none worked in qPCR, so we were
unable to assess the mRNA levels for these two isoforms.
Because one of the major proteins involved in the alternative
splicing of Pkm1/2 mRNA and of the PKM1 protein itself are
not altered (supplemental Fig. S3), it is unlikely that up-regu-
lation of PKM2 under pressure overload is (solely) mediated
by alternative splicing. On the other hand, our data indicate
that increased translation of PKM2 mRNA is mediated by
mTORC1 signaling. Regardless, other factors may also be
involved. Rees et al. (51) reported that, in a sunitinib induced
heart failure mouse model, the PKM2 protein level was up-
regulated by 2-fold, but PKM1 remained unchanged, which is
very similar to what we observed in the TAC rat model. They
also found shift of about 25% from the PKM1 mRNA to the
PKM2 mRNA. This shift was significant but quite subtle com-
pared with the change in protein level (2-fold). Given that
sunitinib also increased insulin sensitivity in mice, it is highly
likely that insulin signaling pathway and increased translation
also contributed to the up-regulation of PKM2 in their model
in addition to alternative splicing. Significantly, our data also
suggest that inhibiting PKM2 might be a new therapeutic
approach for pathological cardiac hypertrophy therefore serv-
ing as a potential biomarker of response to pharmacologic
intervention. However, although inhibitors of PKM2 such as
Shikonin and its analogs have recently been described and
shown to inhibit cancer cell glycolysis (59), it is not clear that
these compounds are suitable as therapeutic agents for tar-
geting PKM2, because they also interact with PKM1 and other
proteins (60).
We also observed increased expression of one elongation
factor (eEF1G), a component of the guanine nucleotide that
controls the activity of eEF1A, an effect that likely contributes
to increasing protein synthesis capacity during pathological
CH.
The healthy heart normally prefers fatty acids as its energy
source (fatty acid oxidation provides about 70% of the ATP in
healthy heart (61). The heart can also use certain other sub-
strates as energy sources, including glucose, lactate, ketones
and amino acids (62, 63). Such flexibility can help maintain
normal function under different workloads and circum-
stances. Metabolic remodeling in heart is a hallmark of CH.
Under hypertrophic conditions, total ATP production de-
creases, and the proportion of ATP generated by fatty acid
oxidation is reduced, whereas ATP generation by glycolysis
and lactate oxidation increases. Interventions that block the
substrate shift from fatty acids to glucose can attenuate TAC-
induced cardiac hypertrophy (61). Our findings indicate that,
following short-term hypertrophic stimulation, the expression
of enzymes involved in glycolysis and the Krebs cycle in-
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creases, likely as an adaptation to the increased demand in
ATP. Although it is commonly accepted that, in failing heart,
genes involved in fatty acid -oxidation are downregulated
(64), our data showed that synthesis rate of -oxidation en-
zymes is also up-regulated soon after hypertrophic stimula-
tion. Our results suggest that myocytes initially attempt to
maintain a high level of -oxidation after hypertrophic stimu-
lation by upregulating those enzymes. However, in the de-
compensation stage of CH, impaired mitochondrial biogene-
sis and mitochondrial defects occur (65), rendering the
up-regulation of those enzymes unfeasible. Interestingly,
analogous traits have been observed with LC-MS-based
quantitative metabolomics studies using a mouse model of
dilated cardiomyopathy (66) and rat TAC hearts (67).
Numerous sarcomeric components/cytoskeletal proteins
were identified as showing increased synthesis in our pSILAC
experiments, several of which play important roles in cardiac
function and/or in cardiomyopathies (e.g. desmin, vinculin,
NRAP (nebulin-related anchoring protein) and Lmod). Muta-
tions or altered expression of those proteins are associated
with various cardiac disorders (68–76). Our data show that
expression of these proteins is regulated by mTORC1 signal-
ing in ARVC.
Indeed, up-regulation of the synthesis of all the proteins we
identified was inhibited by rapamycin indicating it requires
signaling through mTORC1 (Fig. 8). We determined the levels
of the mRNAs for several proteins of interest by RT-qPCR.
mRNA levels were either unchanged or minor indicating that
enhanced synthesis of these proteins involves increased
translation of their mRNAs, rather than increased mRNA lev-
els, consistent with the well-established role of mTORC1 in
controlling mRNA translation. Thus, a key feature of the early
response of ARVC to hypertrophic stimuli is that translational
control underpins the increased synthesis of proteins in re-
sponse to hypertrophic stimuli in ARVC (Fig. 8). We have
previously shown that insulin and PE each activate multiple
components of the translational machinery in ARVC (15, 33,
34, 77).
The greatest effect of rapamycin on the synthesis of a
specific proteins was observed for eEF2, which is encoded by
a TOP mRNA. However, the vast majority of the proteins
whose synthesis was sensitive to rapamycin are not known to
be encoded by TOP mRNAs. Our novel rapid amplification of
cDNA ends (RACE) technique confirmed that the desmin,
AldoA, and Jup mRNAs do not contain a TOP. Thus, the
synthesis of these proteins is increased via an mTORC1-de-
pendent mechanism distinct from the established TOP
regulatory system. Interestingly, some candidate proteins
(ALDOA, MDH2, JUP, ACO2) identified in our pSILAC data are
not only regulated by mTORC1 signaling in ARVC but also in
MEFs. Surprisingly, eEF1G and PKM2 protein levels remained
unchanged in TSC2	/	 cells versus controls (data not shown).
The study results underscore the notion that our optimized
QuaNCAT proteomics approach can more effectively quantify
proteins with very low synthesis rates commonly occurring in
cardiomyocytes. However, a significant number of many pro-
teins were profiled with a high abundance of “light” proteo-
typic peptides relative to their “medium” or “heavy” counter-
parts. Although this difference in ion intensities may have
reduced the linear dynamic range of relative quantitation, this
trend had negligible effects to the study method’s ability to
profile AHA-pSILAC labeled peptides that corresponded to
proteins with low synthesis rates. Such a performance char-
acteristic was extensively verified as part of the method op-
timization experiments. Our proof-of-concept study was in-
tended to assess changes in the synthesis rates of specific
proteins rather than observing the wider spectrum of proteins
typically detected under steady-state conditions using non-
targeted isobaric labeling approaches or label-free ap-
proaches (20–22). Our method selectively analyzed newly
synthesized proteins and exhibited a wide linear dynamic
range capturing proteins occurring at the higher native abun-
dance levels (i.e. cytoskeletal and contractile proteins) that
mapped to the canonical pathway analysis performed as well
as proteins that occur at the lower native abundance levels
(i.e. the translation factors eEF1G and eEF2, PKM2) that con-
stitute novel observations of this study and provide additional
measurable hallmark features in ARVC. Also, the performance
characteristics of our optimized QuaNCAT method in terms of
analytical precision, selectivity, accuracy, and sensitivity su-
persedes that of older radiolabeling approaches (e.g. with
[35S]methionine) for studying the synthesis of specific pro-
teins. There are undoubtedly newly synthesized proteins in
ARVC that are not captured with the method used here be-
cause of intrinsic limitations in the enrichment, purification
and/or subsequent LC-MS detection of peptides. Therefore,
the synthesis of other proteins of potential interest likely
shows differential responses to PE or insulin. This does not
detract from the basic study goal in that measurable and
novel differences were indeed observed between the reported
stimuli in ARVC. Previous studies using label-free and iTRAQ
LC-MS proteomics to study the differential expression of
proteins in hypertrophic or diseased heart (20–22) only exam-
ined steady-state levels of expression, not alterations in their
synthesis rates. Another proteomics study using two-dimen-
sional electrophoresis (2-DE) and MALDI mass spectrometry,
found that, at 48 weeks, when left ventricular hypertrophy was
well established, 56 proteins were differentially expressed in
hearts of spontaneously hypertensive rats compared with
controls (48). The same group reported only nine proteins
were differentially expressed at earlier stages of left ventricu-
lar hypertrophy (22). By contrast, the detection of proteins
exhibiting a varying degree of synthesis rates and native
abundance levels made possible with the QuaNCAT study
method were not observed by these proteomics approaches
even at steady-state concentration levels. Additionally, the
degree of proteome coverage for the de novo synthesized
proteins observed in this study mapped to a wide spectrum of
Translational Control by Hypertrophic Agents in Heart Cells
Molecular & Cellular Proteomics 15.10 3185
 by guest on Septem
ber 4, 2018
http://w
w
w
.m
cponline.org/
D
ow
nloaded from
 
biological pathways and networks thus providing a novel syn-
ergistic understanding of cardiac hypertrophy.
CONCLUSIONS AND FUTURE PERSPECTIVES
Overall, our data show that, rapidly after PE or insulin
stimulation of ARVC, there are substantial changes in the
synthesis rates of proteins involved in various processes
including glycolysis, Krebs cycle, -oxidation, translation,
protein
folding and sarcomeric function. Their regulation requires
mTORC1 signaling, which promotes translation of their
mRNAs. Our data thus reveal that ARVCs respond rapidly to
hypertrophic stimuli by upregulating the synthesis of pro-
teins involved in metabolism and cytoskeletal/contractile
function, although the responses to PE and insulin differ
quantitatively for several proteins. The latter aspect may
well to a considerable extent lead to the differing eventual
outcomes to stimulation of heart muscle cells by PE or
insulin. As a future perspective, the PE and insulin condi-
tions, with or without rapamycin, at the reported concentra-
tions levels provide useful new insight in the design of
functional ARVC in vivo assays to further substantiate these
study conclusions. Finally, we show that two of these pro-
teins, PKM2 and eEF1G, are specifically up-regulated in rats
FIG. 8. Metabolic remodelling model reflected in the distinct patterns of protein synthesis induced by the PE and Insulin in
cardiomyocytes, (see Discussion for details).
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subjected to TAC (Fig. 7 and supplemental Fig. S6). Thus,
our proof-of-principle study has identified PKM2 as a can-
didate biomarker of pathological hypertrophy that warrants
additional functional validation with commercially available
small molecule inhibitors in various in vivo models.
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